MV 130

Drug Profile

MV 130

Alternative Names: Bactek; MV-130

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator Inmunotek
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bacterial infections

Most Recent Events

  • 18 Feb 2016 MV 130 is still in phase III trial for Bacterial infections (Prevention) in Spain (Sublingual) (NCT01842360)
  • 13 Dec 2012 Phase-III clinical trials in Bacterial infections (Prevention) in Spain (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top